CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles

Goujon, Catherine; Gougeon, Marie‐Lise; Tondeur, Laura; Poirier, Béatrice; Seffer, Valérie; Desprès, Philippe; Consigny, Paul‐Henri; Vray, Muriel; Bandé, Valentin; Benabdelmoumen, G.; Bouchaud, Olivier; Bourée, Patrice; Cailhol, Johann; Donne, Jean-Pierre; Faye, Albert; Gergely, Anna; Imbert, Patrick; Kieffer, Yann; Chevallier, Pauline Le; Leclerc, Danielle; Levy, Deborah Salle; Mallard, Adeline; Mornand, Pierre; Pham, Luu-Ly; Poujol, P.; Simian, Philippe; Rapp, C.; Wyplosz, Benjamin

doi:10.1016/j.vaccine.2017.09.047

Cited by 14 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antigenic interference between the live-virus vaccines against measles and yellow fever co-administered under the Expanded Programme on Immunization should be considered as an explanation for the drop in immunity. In some studies, the immunogenicity of the yellow fever vaccine was decreased by co-administration with the measles vaccine, either alone 28 or as part of the measles, mumps, rubella combination 29 . In other studies,30, 38, 39 however, no interference could be shown.…”

Section: Discussionmentioning

confidence: 99%

Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Domingo

Fraissinet

Ansah

et al. 2019

The Lancet Infectious Diseases

View full text Add to dashboard Cite

SummaryBackgroundA single dose of vaccine against yellow fever is routinely administered to infants aged 9–12 months under the Expanded Programme on Immunization, but the long-term outcome of vaccination in this age group is unknown. We aimed to evaluate the long-term persistence of neutralising antibodies to yellow fever virus following routine vaccination in infancy.MethodsWe did a longitudinal cohort study, using a microneutralisation assay to measure protective antibodies against yellow fever in Malian and Ghanaian children vaccinated around age 9 months and followed up for 4·5 years (Mali), or 2·3 and 6·0 years (Ghana). Healthy children with available day-0 sera, a complete follow-up history, and no record of yellow fever revaccination were included; children seropositive for yellow fever at baseline were excluded. We standardised antibody concentrations with reference to the yellow fever WHO International Standard.FindingsWe included 587 Malian and 436 Ghanaian children vaccinated between June 5, 2009, and Dec 26, 2012. In the Malian group, 296 (50·4%, 95% CI 46·4–54·5) were seropositive (antibody concentration ≥0·5 IU/mL) 4·5 years after vaccination. Among the Ghanaian children, 121 (27·8%, 23·5–32·0) were seropositive after 2·3 years. These results show a large decrease from the proportions of seropositive infants 28 days after vaccination, 96·7% in Mali and 72·7% in Ghana, reported by a previous study of both study populations. The number of seropositive children increased to 188 (43·1%, 95% CI 38·5–47·8) in the Ghanaian group 6·0 years after vaccination, but this result might be confounded by unrecorded revaccination or natural infection with wild yellow fever virus during a 2011–12 outbreak in northern Ghana.InterpretationRapid waning of immunity during the early years after vaccination of 9-month-old infants argues for a revision of the single-dose recommendation for this target population in endemic countries. The short duration of immunity in many vaccinees suggests that booster vaccination is necessary to meet the 80% population immunity threshold for prevention of yellow fever outbreaks.FundingWellcome Trust.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Domingo

Fraissinet

Ansah

et al. 2019

The Lancet Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Goujon et al assessed 131 infants; 96% had protective YF antibody levels. All 4 infants without a protective titer of YF antibodies had concurrent MMR and YF administration [59]. YF seropositivity declined in Malian children from 96.7% at 28 days after vaccination to 50.4% at 4.5 years postvaccination; seropositivity also declined in Ghanaian children from 72.7% at 28 days after vaccination to 27.8% at 2.3 years postvaccination [60].…”

Section: Duration Of Protectionmentioning

confidence: 97%

“…There are some concerns regarding subsets of YF vaccine recipients who developed lower antibody responses and/or shorter duration of antibody persistence [4,50,51,57]. In Brazil, seroconversion rates in children were lower when YF vaccine was administered concurrently with measles, mumps, rubella, possibly due to interference from co-administration of these two live-attenuated virus vaccines [58,59]. Goujon et al assessed 131 infants; 96% had protective YF antibody levels.…”

Section: Duration Of Protectionmentioning

confidence: 99%

Yellow fever control: current epidemiology and vaccination strategies

Chen

Wilson

2020

Trop Dis Travel Med Vaccines

View full text Add to dashboard Cite

Yellow fever (YF) outbreaks continue, have expanded into new areas and threaten large populations in South America and Africa. Predicting where epidemics might occur must take into account local mosquito populations and specific YF virus strain, as well as ecoclimatic conditions, sociopolitical and demographic factors including population size, density, and mobility, and vaccine coverage. Populations of Aedes aegypti and Aedes albopictus from different regions vary in susceptibility to and capacity to transmit YF virus. YF virus cannot be eliminated today because the virus circulates in animal reservoirs, but human disease could be eliminated with wide use of the vaccine. WHO EYE (Eliminate Yellow Fever Epidemics) is a welcome plan to control YF, with strategies to be carried out from 2017 to 2026: to expand use of YF vaccine, to prevent international spread, and to contain outbreaks rapidly. YF vaccination is the mainstay in controlling YF outbreaks, but global supply is insufficient. Therefore, dose-sparing strategies have been proposed including fractional dosing and intradermal administration. Fractional dosing has been effectively used in outbreak control but currently does not satisfy International Health Regulations; special documentation is needed for international travel. Vector control is another facet in preventing YF outbreaks, and novel methods are being considered and proposed.

show abstract

“…Further studies have shown that in Brazilian children, the rate of seroconversion was lower when the YF vaccine was received concurrently with other vaccines, such as measles, mumps, and rubella. This condition is possibly related to an interaction given by the co-administration of these two vaccines, both of which are live attenuated [ 92 , 93 ]. Such observations were confirmed by Goujon et al, who found that in a group of 131 children, 4 of them vaccinated with the two aforementioned live attenuated vaccines did not develop a protective antibody titer against YF [ 93 ].…”

Section: Yf Vaccinementioning

confidence: 99%

“…This condition is possibly related to an interaction given by the co-administration of these two vaccines, both of which are live attenuated [ 92 , 93 ]. Such observations were confirmed by Goujon et al, who found that in a group of 131 children, 4 of them vaccinated with the two aforementioned live attenuated vaccines did not develop a protective antibody titer against YF [ 93 ]. Other concerns also arose from the rates of seropositivity in some children, which showed a decrease a few years after YF vaccination.…”

Section: Yf Vaccinementioning

confidence: 99%

Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects

et al. 2022

View full text Add to dashboard Cite

Yellow fever (YF) virus still represents a major threat in low resource countries in both South America and Africa despite the presence of an effective vaccine. YF outbreaks are not only due to insufficient vaccine coverage for insufficient vaccine supply, but also to the increase in people without history of vaccination living in endemic areas. Globalization, continuous population growth, urbanization associated with inadequate public health infrastructure, and climate changes constitute important promoting factors for the spread of this virus to tropical and subtropical areas in mosquito-infested regions capable of spreading the disease. In the present review, we focus on the origin of the virus and its transmission, representing two debated topics throughout the nineteenth century, going deeply into the history of YF vaccines until the development of the vaccine still used nowadays. Besides surveillance, we highlight the urgent need of routine immunization and vaccination campaigns associated to diverse and innovative mosquito control technologies in endemic areas for YF virus in order to minimize the risk of new YF outbreaks and the global burden of YF in the future.

show abstract

CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles

Cited by 14 publications

References 10 publications

Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Yellow fever control: current epidemiology and vaccination strategies

Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects

Contact Info

Product

Resources

About